Overview

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Status:
Active, not recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This is a dose-toleration study designed to investigate and determine the maximum tolerated dose of nanoliposomal irinotecan in adults with recurrent high-grade glioma when administered directly into the tumor using a process called convection-enhanced delivery. (CED)

Phase:

Phase 1

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Ipsen
Merrimack Pharmaceuticals
National Cancer Institute (NCI)
National Institutes of Health (NIH)

Treatments:

Camptothecin
Irinotecan